Harmony Biosciences, LLC (Harmony) presented new data on Pitolisant at the SLEEP 2019 meeting.  Harmony’s goal is to obtain FDA approval to market this new medication in the US in 2019. If approved, pitolisant would represent the first new therapy in the U. in over 15 years for the treatment of both EDS and cataplexy in adult patients with narcolepsy. 

Read more here.